Caffeine Citrate for is used for prevention of Apnea of prem
Caffeine citrate is the most frequently used medication in preterm neonates for the prevention of apnea of prematurity. There is no accepted consensus regarding the optimal caffeine citrate dosing. In this study, researchers evaluate clinical responses of premature neonates to standard-dose caffeine citrate treatment.

A prospective observational study was conducted at the NICU. The study population included preterm neonates born at a gestational age (GA) less than 33 weeks and treated with caffeine citrate according to the local NICU protocol.

--The study cohort included 66 preterm neonates of GA less than 33 weeks.

--30 infants were defined as responders and 36 as nonresponders to 7.5 mg/kg caffeine citrate treatment, and they required a further dose increase to 10 mg/kg.

--Infants in the nonresponders group were born at earlier GA than responders (29 vs. 31 weeks, respectively).

--The nonresponders required a significantly longer hospital stay (56 vs. 46 days), and longer supplemental oxygen support (18 vs 2 days).

To summarize, starting Caffeine citrate at higher dosages is safe and does not necessitate routine serum level monitoring. In preterm neonates born less than 29 weeks of gestation, it might be more successful at controlling prematurity-related apneas.